Who is sponsoring NCT04691622?

NCT04691622 is sponsored by Children's National Research Institute.

What drugs are being tested in NCT04691622?

Interventions in NCT04691622: Norovirus -specific T-cell (NST) therapy.

Is NCT04691622 still recruiting?

NCT04691622 is currently recruiting now. Last updated 26 January 2026.

Last reviewed 2026-01-26 · How we verify

NCT04691622: ATLANTIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

Recruiting now Phase 1 Last updated 26 January 2026

What this trial tests

Phase 1 trial testing Norovirus -specific T-cell (NST) therapy in Viral Infection in 48 participants. Currently enrolling.

Timeline

17 March 2022

Primary endpoint
30 August 2028

30 October 2028

Quick facts

Lead sponsor	Children's National Research Institute
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	17 March 2022
Primary completion	30 August 2028
Estimated completion	30 October 2028
Sites	3 locations across United States

Drugs / interventions tested

Norovirus -specific T-cell (NST) therapy — full drug profile →

Conditions studied

Viral Infection — all drugs for Viral Infection →
Hematopoietic Stem Cell Transplantation (HSCT) — all drugs for Hematopoietic Stem Cell Transplantation (HSCT) →
Primary Immunodeficiency Disorders (PID) — all drugs for Primary Immunodeficiency Disorders (PID) →

Sponsor

Children's National Research Institute

Who can join

Adults 3 Months to 80, any sex, with Viral Infection or Hematopoietic Stem Cell Transplantation (HSCT). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are immunocompromised due to PID and have not undergone HSCT, or Solid Organ Transplant (SOT) recipients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity.
Lewis MA, Cortés-Penfield NW, Ettayebi K, Patil K, et al · · 2023 · cited 26× · PMID 37787556 · DOI 10.1128/aac.00636-23
Reconstitution of Norovirus-Specific T-Cell Responses Following Hematopoietic Stem Cell Transplantation in Patients With Inborn Errors of Immunity and Chronic Norovirus Infection.
Durkee-Shock J, Cohen A, Maghzian N, Pezzella G, et al · · 2025 · cited 5× · PMID 39140311 · DOI 10.1093/infdis/jiae398
Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.
Djassemi N, Hanisch B, Motta C, Maghzian N, et al · · 2025 · cited 2× · PMID 40864193 · DOI 10.1182/bloodadvances.2024013727

Verify or expand the search:

Other recruiting trials for Viral Infection

Currently open trials in the same condition.

NCT06931002 — A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis · NA · recruiting
NCT06271655 — Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Dep · NA · active not recruiting
NCT05671159 — COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted t · NA · recruiting
NCT05246098 — REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI · recruiting
NCT04013802 — TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. · Phase 1 · recruiting

Other Children's National Research Institute trials

Trials by the same sponsor.

NCT07336264 — Characterization of Acute Pain · recruiting
NCT06938542 — Palliative Care Needs of Children With Rare Diseases and Their Families · NA · enrolling by invitation
NCT06618027 — Pragmatic Clinic-Based Trial of a Mindfulness Based Intervention for Mood Concerns in Youth With Type 1 Diabetes · NA · recruiting
NCT06770010 — Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease · NA · recruiting
NCT06623981 — The Exhale Study: Treating Maternal Depression in an Urban Pediatric Asthma Clinic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04691622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's National Research Institute
Last refreshed: 26 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04691622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing